An excerpt of Society for Maternal-Fetal Medicine Consult Series #56: Hepatitis C in pregnancy—updated guidelines: Replaces Consult Number 43, November 2017
10.13604/j.cnki.46-1064/r.2022.12.20
- Author:
ZHONG Si-qi
;
XU He
;
JIANG Liang-kun
;
FAN Jing-hua
- Publication Type:News
- Keywords:
Antiviral therapy;
hepatitis C virus;
screening;
vertical transmission
- From:
China Tropical Medicine
2022;22(12):1211-
- CountryChina
- Language:Chinese
-
Abstract:
Abstract: In the United States, it is estimated that 1% to 4% of pregnant women are infected with hepatitis C virus
（HCV）, which carries approximately a 5% risk of transmission from mother to infant. Hepatitis C virus can be transmitted to
the infant in utero or during the peripartum period, and infection during pregnancy is associated with an increased risk of
adverse fetal outcomes, including fetal growth restriction and low birthweight. The purpose of an excerpt of Society for
Maternal-Fetal Medicine Consult Series #56: Hepatitis C in pregnancy—updated guidelines: Replaces Consult Number 43,
November 2017 is to discuss the current evidence, provide updated recommendations regarding screening, review treatment,
and address management of hepatitis C virus during pregnancy.
- Full text:20.An excerpt of Society for Maternal-Fetal Medicine Consult Series.pdf
